BGI Genomics Co Ltd.
https://www.bgi.com/global/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BGI Genomics Co Ltd.
Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?
Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.
WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act
BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.
US Toning Down China CDMO Tension But New Restrictions Emerge
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.
China Further Tightens Oversight Of Human Genetic Research
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- BGI Europe A/S
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice